In HF with secondary MR at high surgical risk, TEER was noninferior to surgery for CV events and reduced safety events at 1 y.

Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. N Engl J Med. 2024;391:1787-1798.

In adults with AMI who are at risk for HF, empagliflozin did not reduce a composite of first HF hospitalization or all-cause death at 18 mo.

Butler J, Jones WS, Udell JA, et al. N Engl J Med. 2024;390:1455-1466.

In noncardiac thoracic surgery, low-dose colchicine did not reduce AF or myocardial injury after noncardiac surgery at 14 d.

Conen D, Ke Wang M, Popova E, et al; COP-AF Investigators. Lancet. 2023;402:1627-1635.

Reduced dietary sodium did not reduce clinical events in heart failure.

Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Lancet. 2022;399:1391-400.

In patients with MI or high-risk coronary disease, influenza vaccination reduced CV events at 12 mo.

Fröbert O, Götberg M, Erlinge D, et al. Circulation. 2021;144:1476-84.

In patients with stable CVD receiving statins, evolocumab reduced acute arterial events across all vascular territories.

Oyama K, Giugliano RP, Tang M, et al. Eur Heart J. 2021;42:4821-9.

After PCI and short-term DAPT, P2Y12 inhibitors alone vs. ongoing DAPT reduce major bleeding; CV events do not differ.

Malik AH, Yandrapalli S, Shetty SS, et al. Am J Cardiol. 2020;127:25-9.

Hypothesis: Paroxetine, a G Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor Reduces Morbidity and Mortality in Patients With Heart Failure.

The hypothesis that paroxetine decreases morbidity and mortality in patients with heart failure (HF) is plausible but unproven. Basic research demonstrates that inhibition of G protein-coupled receptor kinase 2 (GRK2) both in vitro and in vivo in the myocardium may be beneficial. G protein-coupled receptor kinase 2 antagonism is purported to exert cardioprotective effects immediately following myocardial injury by blunting toxic overstimulation on a recently injured heart.

Non-critical care telemetry and in-hospital cardiac arrest outcomes.

Background: Telemetry is increasingly used to monitor hospitalized patients with lower intensities of care, but its effect on in-hospital cardiac arrest (IHCA) outcomes in non-critical care patients is unknown.

Hypothesis: Telemetry utilization in non-critical care patients does not affect IHCA outcomes.

Methods: A retrospective cohort analysis of all patients in non-critical care beds that experienced a cardiac arrest in a university-affiliated teaching hospital during calendar years 2011 and 2012 was performed.

Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making.

Cyclooxygenase-2 inhibitors were initially developed, then received regulatory approval and were subsequently widely marketed to achieve effective pain relief in patients with inflammatory conditions while decreasing gastrointestinal complications. Gastrointestinal symptoms as well as signs had been a major concern with the use of traditional non-steroidal anti-inflammatory drugs. Individual clinical judgements about the prescription of cyclooxygenase-2 inhibitors and non-steroidal anti-inflammatory drugs for relief of pain from inflammatory arthritis should not be limited to risks of cardiovascular disease but should also consider gastrointestinal complications, symptoms as well as signs, and other benefits which include, but are not limited to improvements in quality of life resulting from decreases in pain or impairment from musculoskeletal pain syndromes.

Aspirin increases nitric oxide formation in chronic stable coronary disease.

Introduction: There are no published randomized data on secondary prevention in humans about whether aspirin affects nitric oxide (NO) formation. In patients with chronic stable coronary disease, we tested whether aspirin at clinically relevant doses increases NO formation.

Materials And Methods: In a randomized, double-blind trial, 37 patients from 2 cardiology office practices were assigned to daily doses of 81, 162.

Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction.

Patients with heart failure (HF) are at increased risk for drug-induced torsades de pointes (TdP) due to unknown mechanisms. Our objective was to determine if sensitivity to drug-induced QT interval lengthening is enhanced in patients with HF. In this multicenter, prospective study, 15 patients with atrial fibrillation or flutter requiring conversion to sinus rhythm were enrolled: 6 patients with New York Heart Association class II to III HF (mean ejection fraction [EF], 30% ± 9%), and 9 controls (mean EF, 53% ± 6%).

Do Statins Reduce Atrial Fibrillation After Coronary Artery Bypass Grafting?

Atrial Fibrillation (AF) is a common postoperative complication after coronary artery bypass grafting. There is contradictory evidence as to whether pre-operative statin use lowers the incidence of postoperative AF. This study aimed to assess whether pre operative statin therapy prevents the post-operative AF.

Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.

Study Objective: To assess whether the increased risk of ibutilide-induced torsade de pointes in patients with heart failure may be due to increased ibutilide exposure, we sought to determine if the pharmacokinetics of ibutilide are altered in patients with heart failure due to left ventricular systolic dysfunction.

Design: Multicenter, prospective pharmacokinetic study.

Setting: Four academic medical centers in the United States.